Mei Zheng

Dr. Mei Zheng

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
DDDuy Trong Vien Diep
Duy Trong Vien Diep
KHKyungki Hong
Kyungki Hong
TKTriyeng Khun
Triyeng Khun
MZMei Zheng
Mei Zheng
AHAsad Haq
Asad Haq
KCKwang-Hoon Chun
Kwang-Hoon Chun
Adipose tissue is a specialized organ that synthesizes and stores fat. During adipogenesis, Rho and Rho-associated kinase (ROCK) 2 are inactivated, which enhances the expression of pro-adipogenic genes and induces the loss of actin stress fibers. Furthermore, pan ROCK inhibitors enhance adipogenesis in 3T3-L1 cells. Here, we show that KD025 (formerly known as SLx-2119), a ROCK2-specific inhibitor, suppresses adipogenesis in 3T3-L1 cells partially through a ROCK2-independent mechanism. KD025 downregulated the expression of key adipogenic transcription factors PPARγ and C/EBPα during adipogenesis in addition to lipogenic factors FABP4 and Glut4. Interestingly, adipogenesis was blocked by KD025 during days 1~3 of differentiation; after differentiation terminated, lipid accumulation was unaffected. Clonal expansion occurred normally in KD025-treated cells. These results suggest that KD025 could function during the intermediate stage after clonal expansion. Data from depletion of ROCKs showed that KD025 suppressed cell differentiation partially independent of ROCK’s activity. Furthermore, no further loss of actin stress fibers emerged in KD025-treated cells during and after differentiation compared to control cells. These results indicate that in contrast to the pro-adipogenic effect of pan-inhibitors, KD025 suppresses adipogenesis in 3T3-L1 cells by regulating key pro-adipogenic factors. This outcome further implies that KD025 could be a potential anti-adipogenic/obesity agent.

31 January 2019 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
MZMei Zheng
Mei Zheng
YJY.‐J. Jang
Y.‐J. Jang
NCN. Choi
N. Choi
DKD. Y. Kim
D. Y. Kim
THT. W. Han
T. W. Han
JSJong-Hyuk Sung
Jong-Hyuk Sung

Verified
Journal Article
Open access
PDF file
SASeungchan An
Seungchan An
MZMei Zheng
Mei Zheng
IPIn Guk Park
In Guk Park
LSLeegu Song
Leegu Song
JKJino Kim
Jino Kim
JSJong-Hyuk Sung
Jong-Hyuk Sung
Androgenetic alopecia (AGA) is a common form of hair loss characterized by androgen-driven tissue remodeling, including progressive follicular miniaturization and dermal fibrosis, which is accompanied by low-grade immune activation. However, the molecular mechanisms underlying this fibroimmune dysfunction remain poorly understood. Dermal fibroblasts (DFs) have been suggested as androgen-responsive stromal cells and a potential source of CXCL12, a chemokine implicated in fibroimmune pathology, but their precise role in AGA has not been fully established. In this study, we performed single-cell transcriptomic profiling of a testosterone-induced mouse model of AGA, with or without treatment of CXCL12-neutralizing antibody, to elucidate the pathological role of CXCL12 in mediating stromal-immune interactions. Our analysis suggested that DFs are the primary androgen-responsive population driving CXCL12 expression. Autocrine CXCL12-ACKR3 signaling in DFs activated TGF-β pathways and promoted fibrotic extracellular matrix deposition. In parallel, paracrine CXCL12-CXCR4 signaling reprogrammed Sox2+Twist1+ dermal papilla cells (DPCs) and promoted the accumulation of pro-fibrotic Trem2+ macrophages, contributing to impaired hair follicle regeneration. Notably, CXCL12 blockade attenuated these stromal and immune alterations, restored the regenerative capacity of DPCs, reduced pro-fibrotic macrophage infiltration, and promoted hair regrowth. Together, these findings identify CXCL12 as a central mediator of androgen-induced fibroimmune remodeling and highlight its potential as a therapeutic target in AGA.

1 December 2020 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
XZXiaohan Zhang
Xiaohan Zhang
MZMei Zheng
Mei Zheng
Kyeong-Man KimKyeong-Man Kim
Kyeong-Man Kim

Verified
Journal Article
Open access
PDF file
MZMei Zheng
Mei Zheng
SASeungchan An
Seungchan An
IPIn Guk Park
In Guk Park
JKJino Kim
Jino Kim
WKWon Serk Kim
Won Serk Kim
JSJong-Hyuk Sung
Jong-Hyuk Sung
We previously demonstrated that C-X-C Motif Chemokine Ligand 12 (CXCL12) is primarily secreted by dermal fibroblasts in response to androgens and induces hair miniaturization in the mouse androgenic alopecia (AGA) model. However, the direct effects of androgen-induced CXCL12 on dermal papilla cells (DPCs) and dermal sheath cup cells (DSCs) have not been demonstrated. First, we compared single-cell RNA sequencing data between mouse and human skin, and the results show that CXCL12 is highly co-expressed with the androgen receptor (AR) in the DPCs and DSCs of only human hair. Immunohistochemistry also showed that CXCL12 is co-expressed with the AR in the DPCs and DSCs of human hair follicles. In human hair organ culture, androgens also increased CXCL12 expression in DPCs and DSCs and reduced hair length, while the CXCL12 antibody increased hair length via AR inactivation. CXCL12 mRNA was upregulated by androgen treatment in primary human DPCs and DSCs. On the contrary, AR inhibitors or siRNA treatment reduced CXCL12 expression. Collectively, these results suggest that CXCL12 is co-expressed with the AR in the DPCs and DSCs of human hair follicles; therefore, inhibition of CXCL12 using antibodies is a promising strategy for AGA treatment.

7 November 2018 in Journal of Pharmaceutical Investigation
Verified
Journal Article
Closed access
PDF file
MZMei Zheng
Mei Zheng
DKDoo-Yeong Kim
Doo-Yeong Kim
JSJong-Hyuk Sung
Jong-Hyuk Sung